Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes, a gram-positive bacterium to which individuals with weakened immune systems are susceptible. Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an important...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.